Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 17:2022:5338956.
doi: 10.1155/2022/5338956. eCollection 2022.

Association of β-Catenin, APC, SMAD3/4, Tp53, and Cyclin D1 Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis

Hongfeng Yan  1 , Fuquan Jiang  1 , Jianwu Yang  1
Affiliations
Meta-Analysis

Association of β-Catenin, APC, SMAD3/4, Tp53, and Cyclin D1 Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis

Hongfeng Yan et al. Genet Res (Camb). .

Abstract

Objectives: Accumulating evidence indicates that the expression and/or variants of several genes play an essential role in the progress of colorectal cancer (CRC). The current study is a meta-analysis undertaken to estimate the prognosis and survival associated with CTNNB1/β-catenin, APC, Wnt, SMAD3/4, TP53, and Cyclin D1 genes among CRC patients.

Methods: The authors searched PubMed, EMBASE, and Science Direct for relevant reports published between 2000 and 2020 and analyzed them to determine any relationship between the (immunohistochemically/sequencing-detected) gene expression and variants of the selected genes and the survival of CRC patients.

Results: The analysis included 34,074 patients from 64 studies. To evaluate association, hazard ratios (HRs) were estimated for overall survival (OS) or disease-free survival (DFS), with a 95% confidence interval (CIs). Pooled results showed that β-catenin overexpression, APC mutation, SMAD-3 or 4 loss of expression, TP53 mutations, and Cyclin D1 expression were associated with shorter OS. β-Catenin overexpression (HR: 0.137 (95% CI: 0.131-0.406)), loss of expression of SMAD3 or 4 (HR: 0.449 (95% CI: 0.146-0.753)), the mutations of TP53 (HR: 0.179 (95% CI: 0.126-0.485)), and Cyclin D1 expression (HR: 0.485 (95% CI: 0.772-0.198)) also presented risk for shorter DFS.

Conclusions: The present meta-analysis indicates that overexpression or underexpression and variants of CTNNB1/β-catenin, APC, SMAD3/4, TP53, and Cyclin D1 genes potentially acted as unfavorable biomarkers for the prognosis of CRC. The Wnt gene was not associated with prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow chart of the selected studies.
Figure 2
Figure 2
Forest plot of β-catenin gene and overall survival in CRC (a). Forest plot of β-catenin gene and disease-free survival in CRC (b).
Figure 3
Figure 3
Forest plot of APC gene and overall survival in CRC (a). Forest plot of APC gene and disease-free survival in CRC (b).
Figure 4
Figure 4
Forest plot of SMAD3/4 gene and overall survival in CRC (a). Forest plot of SMAD3/4 gene and disease-free survival in CRC (b).
Figure 5
Figure 5
Forest plot of TP53 gene and overall survival in CRC (a). Forest plot of TP53 gene and disease-free survival in CRC (b).
Figure 6
Figure 6
Forest plot of WNT gene and overall survival in CRC.
Figure 7
Figure 7
Forest plot of Cyclin D1 gene and overall survival in CRC (a). Forest plot of cyclin D1 gene and disease-free survival in CRC (b).
Figure 8
Figure 8
The funnel plot of studies included for APC gene and OS in CRC (a). The funnel plot of studies included for SMAD gene and OS in CRC (b). The funnel plot of studies included for β-catenin gene and OS in CRC (c). The funnel plot of studies included for β-catenin gene and DFS in CRC (d). The funnel plot of studies included for TP53 gene and OS in CRC (e). The funnel plot of studies included for TP53 gene and DFS in CRC (f).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rawla P., Sunkara T., Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad Gastroenterolgiczny . 2019;14(2):89–103. - PMC - PubMed
    1. Mohd Y., Balasubramanian B., Meyyazhagan A., et al. Extricating the association between the prognostic factors of Colorectal Cancer. Journal of Gastrointestinal Cancer . 2021;52(3):1022–1028. - PubMed
    1. Li J., Ma X., Chakravarti D., Shalapour S., DePinho R. A. Genetic and biological hallmarks of colorectal cancer. Genes & Development . 2021;35(11-12):787–820. doi: 10.1101/gad.348226.120. - DOI - PMC - PubMed
    1. Luo X. J., Zhao Q., Liu J., et al. Novel genetic and epigenetic biomarkers of prognostic and predictive significance in stage ii/iii colorectal cancer. Molecular Therapy . 2021;29(2):587–596. doi: 10.1016/j.ymthe.2020.12.017. - DOI - PMC - PubMed
    1. Labadie J. D., Savas S., Harrison T. A., et al. Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival. Scientific Reports . 2022;12(1) doi: 10.1038/s41598-021-03945-x. - DOI - PMC - PubMed